Summary We examined 159 consecutive cases of non-small-cell lung cancer (NSCLC) for a mutation at codon 12 of the K-ras gene and for a mutation of the p53 gene occurring in exons 5-8. Eleven (6.9%) had mutations of the K-ras (ras+) and 57 (35.8%) had mutations of the p53 (p53+). There were 95 cases (59.7%) with ras -p53 -, seven cases (4.4%) with ras+/p53 -, 53 cases (33.3%) with ras -/p53+ and four cases (2.5%) with ras+/p53+. The ras+ group had a worse prognosis than the ras -group in all cases and in 107 early-stage cases (stage l-ll, P<0.05). The p53+ group had a worse prognosis in 107 early-stage cases (P<0.01), but there was no statistically significant difference when 52 advanced-stage cases (stage III-IV) or all patients were considered. Both ras and p53 mutations were unfavourable prognostic factors in 94 cases with adenocarcinoma, but there was no statistical significance in 57 cases with squamous cell carcinoma. According to Cox's model, the pathological stage, ras mutation and p53 mutation were found to be independent prognostic factors. Our results suggest that ras and p53 mutations were independent unfavourable prognostic markers especially in the early stage of NSCLC or in adenocarcinoma.
Lung cancer has one of the most unfavourable prognoses among the various human malignant tumours. We sometimes experience early recurrence in early-stage patients and it is not rare for distant metastases to occur after a complete resection of small cancers measuring less than 2 cm in diameter. However, it is often difficult to distinguish these unfavourable patients from others with a better prognosis based on the existing diagnostic tools.
Recent advances in molecular biology have now enabled us to identify various oncogenes and tumour-suppressor genes that are involved in carcinogenesis and the progression of cancer. In nonsmall-cell lung cancer (NSCLC), mutations of the ras oncogene and p53 tumour-suppressor gene are two of the most frequent genetic alterations detected so far (Minna, 1993) .
A ras gene mutation is detected in 10-30% of NSCLC cases, and 80% of ras mutations occurred at codon 12 of the K-ras gene (Rodenhuis et al, 1988; Bos et al, 1989; Slebos et al, 1990; Mitsudomi et al, 1991a,b; Sugio et al, 1992) . ras mutations are more frequent in adenocarcinoma than in squamous cell carcinoma but are absent in small-cell lung cancer (Rodenhuis et al, 1988; Mitsudomi et al, 199 ib). Several investigators have reported that ras mutations are a poor prognostic factor in NSCLC (Slebos et al, 1990; Mitsudomi et al, 1991a) . Our group also indicated that ras mutations are a poor prognostic marker in node-negative adenocarcinoma in human lung cancer (Sugio et al, 1992) .
On the other hand, the p53 gene is one of the most frequently mutated tumour-suppressor genes in human tumours. The p53 gene regulates the cell cycle negatively through the transactivation of the p21/Waf] gene and, in some cases, it induces apoptosis through the transactivation of the Bax gene (El-Deiry et al, 1993; Selvakumaran et al, 1994) . In NSCLC, p53 mutations are found in about half of the tumours (Iggo et al, 1990; Levine et al, 1991; McLaren et al, 1992; Miller et al, 1992; Suzuki et al, 1992; Mitsudomi et al, 1992 Mitsudomi et al, , 1993 Passlick et al, 1995) , and it is more frequent in squamous cell carcinoma than in adenocarcinoma (Iggo et al, 1990; McLaren et al, 1992; Miller et al, 1992; Mitsudomi et al, 1993; Passlick et al, 1995) . It is controversial, however, as to whether the presence of p53 gene mutations in NSCLC has any prognostic value (McLaren et al, 1992; Horio et al, 1993; Mitsudomi et al, 1993; Passlick et al, 1995; Lee et al, 1995) .
It has been reported that the mutated ras gene requires an immortalizing gene, such as either myc or a mutated p53 gene, to transform primary rat embryo fibroblasts in vitro (Land et al, 1983; Eliyahu et al, 1984; Parada et al, 1984; Yancopoulos et al, 1985; Hunter, 1991) . However, it has not been clarified as to whether ras and p53 mutations combine to result in an unfavourable prognosis for patients with NSCLC.
In this study, we simultaneously evaluated ras gene and p53 gene mutations and tried to correlate the findings with the prognoses of patients with NSCLC who had been surgically treated consecutively in our department.
MATERIALS AND METHODS Patients and tumour samples
From April 1990 to December 1993, 162 consecutive Japanese patients with NSCLC underwent a pulmonary resection at the Second Department of Surgery, Kyushu University Hospital. Excluding four samples with poor preservation, 159 samples (one case had double primary lung cancer of adenocarcinoma and squamous cell carcinoma) were included in this study. They included 103 men and 56 women, with ages ranging from 35 to 82 years (median 65 years). There were 94 patients with adenocarcinoma, 57 with squamous cell carcinoma, four with large-cell carcinoma and four with adenosquamous cell carcinoma. According to the TNM classification system, 82 patients were stage I, 25 were stage II, 26 were stage IIIA, 11 were stage IIIB and 15 were stage IV. The median follow-up period was 624 days (range 30-1660 days). These 159 tumour tissue samples (155 frozen materials and four formalin-fixed paraffin-embedded materials) were examined for mutations of the ras and p53 genes [46 cases were also analysed for ras mutation in our previous study (Sugio et al, 1992) ].
DNA preparation
From the frozen samples and the formalin-fixed paraffinembedded samples, high molecular weight DNA was isolated as described previously (Sugio et al, 1988) . These high molecular weight DNAs were stored in a TE buffer (10 mm Tris-HCI, 1 mM EDTA, pH 8.0) at 4°C until the time of examination.
Detection of the point mutation at codon 12 of the K-ras oncogene Although ras mutations occur either at codons 12, 13 and 61 of the K-, H-and N-ras oncogene in various human cancers (Bos, 1989) , about 80% of all ras mutations are at codon 12 of the K-ras gene in NSCLC (Rodenhuis et al, 1988; Bos et al, 1989; Slebos et al, 1990; Mitsudomi et al, 1991a,b; Sugio et al, 1992) . In fact, in our previous study (Sugio et al, 1992) , 15 of 18 ras mutations (83%) were present at this particular codon. Therefore, we concentrated our effort on codon 12 of the K-ras gene to avoid any unnecessarily extensive screening. A polymerase chain reaction (PCR)/designed restriction fragment length polymorphism (RFLP) analysis using a mismatched primer was done to detect the point mutations at codon 12 of the K-ras gene as described previously (Mitsudomi et al, 1991b) . Our method was able to detect all six possible mutations occurring at codon 12 of the K-ras gene (Mitsudomi et al, 1991b) . This method could also detect at least 10% of mutant alleles in a background of wild-type allele.
Detection of the point mutations of the p53 tumoursuppressor gene Four fragments of DNA, each encompassing exons 5-8 of the p53 gene, were amplified by the PCR technique. The nucleotide sequences of the primers and the PCR conditions are available upon request. The detection of point mutations of the p53 gene was done by using a single-strand conformation polymorphism (SSCP) technique (Orita et al, 1989) . The PCR product was diluted 1:8 with a loading buffer, and loaded on to four types of gels containing either 8% or 12% polyacrylamide with or without 5% glycerol in order to raise the sensitivity for detecting a mutation. The size of the gel was 14 x 13 cm. Electrophoresis was done in an air-conditioned room at 10°C with a cooling fan for over 8 h in order to detect mutated bands. The gel was subsequently silver stained using a commercial kit (Silver Stain 'DAIICHI', Daiichi Pure Chemicals, Tokyo, Japan).
Statistical analysis
The data were analysed by Student's t-test and the x2 test in a unifactorial analysis of various clinical and pathological factors. The survival curve was created by the Kaplan-Meier method (Kaplan and Meier, 1958) and statistical significance was calculated by the log rank test (Peto et al, 1977) . We calculated a 75% survival time as the indicator for prognosis, because some of the subgroups did not reach the median survival time during the observation period. Cox's multivariate regressions analysis (Kalbfleisch and Prentice, 1980; Hopkins, 1990) was performed to select independent factors affecting the overall survival. The difference was considered to be significant when the two-sided P-value was less than 0.05.
RESULTS

Frequency of ras mutation and p53 mutation
Of the 159 specimens examined, 11 samples (6.9%) had a mutation of the K-ras gene at codon 12, while 57 samples (35.8%) had a mutation of the p53 gene. Twenty-one of the p53 mutations were in exon 5, five in exon 6, 17 in exon 7 and 17 in exon 8 (three samples with double mutations in exon 6 and 7, 5 and 8, 7 and 8). Ninety-five samples (59.7%) had neither ras nor p53 mutations (ras -/p53 -), seven (4.4%) had only ras mutations (ras+/p53 -), 53 (33.3%) had only p53 mutations (ras -/pS3+) and four (2.5%) had both ras and p53 mutations (ras -/p53+). The incidence of ras mutations in the p53 mutation group (4/57, 7.0%) was not significantly different from that in a p53 wild-type group (7/102, 6.9%), which suggested that ras mutations and p53 mutations occurred independently of each other (P=1.00).
Clinical and pathological status (Table 1) There was a tendency for ras+ cases to be more frequent in adenocarcinoma (10%) than in squamous cell carcinoma (2%) (P=0.09). On the other hand, p53 mutations were more frequent in squamous cell carcinoma (46%) than in adenocarcinoma (27%) (P=0.01). p53 mutations were more prevalent in men (47%) than in women (16%). The Brinkman Index (number of cigarettes per day x years) for pS3+ tumours (800) was higher than that for p53 -tumours (360) significant impact on the survival of patients with squamous cell carcinoma (Figure 1) . Unfortunately, owing to the low mutation rate, no conclusions could be made regarding the effect of ras gene mutations on the prognosis of patients with squamous cell carcinoma.
When both ras and p53 mutations were considered, as expected, the ras -IpS3 -group had the longest survival, while the ras+lp53 -and ras+lp53+ group had a similarly poor prognosis and the ras -/p53+ group had an intermediate prognosis (Figure 2A) . The difference between the ras -/p53 -group and the other three groups was statistically significant. When this analysis was done with a stratification of disease stage, the effects of ras and p53 mutations were greater in a subset of 107 patients with early disease ( Figure 2B ) than in those with advanced disease ( Figure 2C ).
Cox's multivariate regression analysis (Table 3) To see which independent factors had a jointly significant effect on overall survival, we performed Cox's multivariate regression analysis. The potential prognostic variables initially included were age (70 years or under vs over 70 years), sex (men vs women), the Brinkman index (400 or under vs over 400), the pathological stage (stages I and II vs III and IV), histological type (adenocarcinoma vs squamous cell carcinoma), histological differentiation (well or moderately differentiated vs poorly differentiated), ras mutation (ras+ vs ras -) and p53 mutation (pS3+ vs pS3 -). After a stepwise selection of the variables, pathological stage, ras mutation and p53 mutation were all recognized as independent prognostic factors. The relative risk of death for the ras+ patients and the pS3+ patients was 5.6 and 2.2 respectively. Therefore, the relative risk of death for patients with ras+/pS3+ tumours was calculated to be 12.3 (2.2 x 5.6) compared with that of patients with neither of the two mutations.
DISCUSSION
We examined 159 NSCLC patients for both K-ras mutations occurring at codon 12 and p53 mutations occurring in exons 5-8.
British Journal of Cancer (1997) 75(8) Years after operation Mutations at codon 12 of the K-ras gene were found in 6.9% of NSCLC tumours, with a tendency for ras+ cases to be more frequent in adenocarcinoma than in squamous cell carcinoma, as has been reported previously (Rodenhuis et al, 1988) . This incidence is a little low compared with that reported previously (Rodenhuis et al, 1988; Sugio et al, 1992) . We also noted that the incidence of K-ras mutations in tumours resected before 1990 was somewhat higher (13.0%, 15/115). The incidence appeared to decline with time. In tumours resected from 1990 to 1991 the incidence was 11.3% (8/71) and in tumours from 1992 or later it was 3.4% (3/88) in this study. We have no explanation for this change, but the low incidence is not caused by low sensitivity of our assay. We could confirm all K-ras mutations at codon 12 that had been detected by the dot-blotting method using allele-specific probes in our previous study. This change in the incidence of ras mutations may thus reflect a change in the lung cancer aetiology in Japan. Although adenocarcinoma of the lung has been on the increase in Japan, this increase may result from adenocarcinomas that are not associated with K-ras gene mutations. Previous studies, including ours, showed that ras mutations are one of the unfavourable prognostic factors (Slebos et al, 1990; Mitsudomi et al, 1991a; Sugio et al, 1992) . By subsequently adding 113 patients, we were able to confirm the prognostic impact of ras gene mutation.
British Journal of Cancer (1997) A p53 mutation was detected in 35.8% of the cases with a tendency for p53+ cases to be more frequent in squamous cell carcinoma than in adenocarcinoma, thus confirming the previous results (Iggo et al, 1992; Kishimoto et al, 1992; McLaren et al, 1992; Mitsudomi et al, 1993) . We found that p53 mutation was a significant prognostic factor in 107 cases with early-stage disease (stages I and II) (P=0.01) but when all patients were considered, p53 mutation was not found to be a prognostic marker (P=0.20). However, Cox's multivariate regression analysis indicated that p53 mutations were an independent, unfavourable prognostic factor. The effect of these mutations might have been diluted in advanced-stage patients, since advanced lung cancer is a heterogeneous group of patients, i.e. some patients have chest wall invasion without lymph node involvement, while others have bulky metastasis to the mediastinal lymph nodes. p53 mutations were an unfavourable prognostic factor in patients with adenocarcinoma but not at all in patients with squamous cell carcinoma, in spite of its higher frequency. These findings are also in accordance with previous reports including ours, dealing with a different set of NSCLC patients (Mitsudomi et al, 1995; Nishio et al, 1996) . This fact may therefore suggest that p53 mutations play a different role in adenocarcinoma and in squamous cell carcinoma. The prognostic impact of p53 gene mutation is still controversial. Some studies have reported that p53+ cases had a worse prognosis (Mitsudomi et al, 1993; Horio et al, 1993) , while others reported the opposite results (Passlick et al, 1995; Lee et al, 1995 (Raycroft et al, 1990) or binding to the heat shock protein (Hind et al, 1990) , and p53 mutations in the zinc-binding domains L2 (codons and L3 (codons 236-251) are also associated with a poor prognosis in breast cancer (Borresen et al, 1995) . These facts may also account for some of the discrepancies among the different studies. Our data suggested that ras and p53 mutations occur independently and correlated with the findings of previous reports (Mitsudomi et al, 1992; Kishimoto et al, 1992 ). Cox's multivariate regression analysis revealed that ras mutation and p53 mutation were independent prognostic markers together with pathological stage (see Table 3 ). It is thus calculated that ras+/p53+ cases will have a worse prognosis with a relative risk of death of 12.3 compared with ras -Ip53 -cases.
It is believed that human cancer occurs and develops with an accumulation of multiple genetic alterations (Weinberg, 1989; Fearon and Vogelstein, 1990) . Previous reports revealed that alterations of myc, c-erbB-2, bcl-2, RB and MTSJ/p16 genes are involved in the pathogenesis and development of NSCLC in addition to the ras and p53 genes (Minna, 1993) . Furthermore, putative tumour-suppressor genes at chromosomes 3p, 5q, 8p and lIp are also believed to play a role in NSCLC (Minna, 1993) . Although not all of these genetic alterations may be prognostic indicators, our results suggested that ras and p53 mutations are an independent poor prognostic marker in NSCLC. Kern et al (1994) I of ras and erbB-2 is an independent poor prognostic indicator in lung adenocarcinoma, while Xu et al (1994) reported that the loss of retinoblastoma susceptibility gene product expression and the nuclear accumulation of the p53 protein independently contribute to the adverse outcome in stage I and II lung cancer. Further studies dealing with a larger number of patients (possibly in a prospective fashion) are needed to elucidate the prognostic impact of various genetic alterations in NSCLC. It remains to be clarified, however, whether or not the prognosis of NSCLC patients with these poor genetic markers can be improved by either aggressive or investigational therapeutic approaches.
